Back to search results

Semaglutide to Prevent Weight Gain After Liver Transplant

This study is testing if semaglutide, an FDA-approved medication for obesity and Type 2 Diabetes, can prevent weight gain after a liver transplant. Researchers also want to see if semaglutide can stop the development of Non-Alcoholic Fatty Liver Disease (NAFLD) in your new liver. You may be able to join if you are 18-75 years old, had a liver transplant 8-24 weeks ago, and have high blood sugar or diabetes. The study will compare semaglutide to a placebo (an inactive substance) over 72 weeks. Success would mean participants on semaglutide gain less weight and develop less NAFLD. The current status of this study is unclear.

Study design
This is a randomized, double-blinded study, meaning participants are randomly assigned to receive either semaglutide or a placebo, and neither you nor your doctors will know which you are receiving. It plans to enroll 50 participants.
What's involved
You would receive weekly injections of either semaglutide or a placebo for 72 weeks. The dose of semaglutide would gradually increase over the first 20 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your weight will be measured at the start of the study and again at 72 weeks to see the change over time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05424003

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

Recruiting
PHASE2Ages 18–75InterventionalPrevention
University of Virginia
~50 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:Semaglutide Pen InjectorPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in weight
Measured over Baseline to week 72

Conditions

NAFLD

Explore related trials

Liver TransplantationNonalcoholic Fatty Liver Disease

Where it's being run

1 sites across 1 states
Virginia1

Study leadership

  • Mohammad S Siddiqui, MD · PRINCIPAL_INVESTIGATOR · Virginia Commonwealth University

Who to contact

Sherry Boyett, RN
[email protected]
804-828-5434
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female age 18-75 years who received LT for any indication (i.e. NASH, hepatitis C, alcohol-induced cirrhosis, autoimmune hepatitis, etc.)
Liver transplant surgery within 8-24 weeks prior to randomization
Fasting glucose \> 125 mg/dL or presence of diabetes (HbA1c≥6.5% or use of diabetes medications) or pre-diabetes (HbA1c \>5.7%)
Ability to provide informed consent
Discharged from the hospital following LT surgery
Tolerating diet
Normal graft function\* (determined by treating hepatologist/surgeon based on clinical status and hepatic panel)
Stable immunosuppression according the VCU (Virginia Commonwealth University) post-LT protocols \*\* (i.e. calcineurin inhibitors + mycophenolate)
Eligible female patients will be (1) non-pregnant, evidenced by a negative urine pregnancy test, (2) non-lactating, (3)surgically sterile or post-menopausal, or they will agree to continue to use an accepted method of birth control during the study

Exclusion

BMI≤ 27kg/m2
GFR (Glomerular Filtration Rate) ≤ 25 ml/min/1.73m2
Type 1 autoimmune diabetes (by anti-GAD (glutamic acid decarboxylase) or history of ketoacidosis)
History of gastroparesis
Familial or personal history of medullary thyroid cancer or MEN (Multiple Endocrine Neoplasia) 2
History of pancreatitis
History of active malignancy post- LT with the exception of non-melanoma skin cancers
History of uncontrolled or unstable diabetic retinopathy or maculopathy
Acute cellular rejection
Hepatic artery thrombosis
Medical non-compliance
Active treatment with GLP (glucagon-like peptide)-1RA (receptor agonist) or SGLT (sodium-glucose cotransporter)-2 inhibitors at time of screening
History of hypersensitivity to semaglutide or its excipients
Women who are nursing, pregnant, or planning to become pregnant during the study, or are not using adequate contraceptive measures

What this trial measures

  • Change in weightBaseline to week 72

    Weight measured in kilograms